Central European Leukemia Study Group Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2004
NCT00327262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 3 Trials (1)

imatinib (gleevec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 1